63 related articles for article (PubMed ID: 1359619)
1. [Low doses of azidothymidine in the treatment of HIV-1 virus infection].
Lobato-Mendizábal E; Ruiz-Argüelles GJ
Rev Invest Clin; 1992; 44(2):161-8. PubMed ID: 1359619
[TBL] [Abstract][Full Text] [Related]
2. [Preliminary report on the effect of low doses of azidothymidine (AZT) in the treatment of patients with stage III infection by human immunodeficiency virus (HIV)].
Lobato-Mendizábal E; Ruiz-Argüelles GJ; García-Gallardo E; Marín-López A; Marín-López E
Rev Invest Clin; 1990; 42(2):88-92. PubMed ID: 1980026
[TBL] [Abstract][Full Text] [Related]
3. Zidovudine and lamivudine: results of phase III studies.
Staszewski S
J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S57. PubMed ID: 8595510
[TBL] [Abstract][Full Text] [Related]
4. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204
[TBL] [Abstract][Full Text] [Related]
5. The efficacy and toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex (ARC): an open uncontrolled treatment study.
Stambuk D; Youle M; Hawkins D; Farthing C; Shanson D; Farmer R; Lawrence A; Gazzard B
Q J Med; 1989 Feb; 70(262):161-74. PubMed ID: 2512592
[TBL] [Abstract][Full Text] [Related]
6. Azidothymidine (AZT) in the treatment of symptomatic HIV-1-infected hemophiliacs.
Eichinger S; Pabinger I; Hartl H; Stain C; Mayerhofer S; Schweiger C; Kier P; Schwarzinger I; Kyrle PA; Lechner K
Thromb Haemost; 1990 Aug; 64(1):108-12. PubMed ID: 1980381
[TBL] [Abstract][Full Text] [Related]
7. Survival of patients with advanced HIV infection treated with 300 mg/d of zidovudine: a prospective study.
Ruiz-Argüelles GJ; Lagunes-Yannelli B; Mercado-Díaz L; Alemán-Hoey DD
Rev Invest Clin; 1994; 46(6):491-3. PubMed ID: 7899741
[TBL] [Abstract][Full Text] [Related]
8. Acyclovir improves survival time.
Common Factor; 1995 Apr; (no 10):14. PubMed ID: 11362339
[TBL] [Abstract][Full Text] [Related]
9. [Comparative study of various biological markers in HIV 1 infection].
Serra JE; Pombo V; Côrte-Real R; da Cunha S; Meliço-Silvestre A
Acta Med Port; 1993 Jan; 6(1):5-9. PubMed ID: 8097351
[TBL] [Abstract][Full Text] [Related]
10. [Sequential dideoxycytidine and zidovudine in advanced HIV-1 infection. Phase II study].
Ruiz-Argüelles GJ; Lagunes-Yannelli B; Mercado-Díaz L
Rev Invest Clin; 1993; 45(2):145-7. PubMed ID: 8393211
[TBL] [Abstract][Full Text] [Related]
11. Report on a 3-year follow-up zidovudine (AZT) treatment in a group of HIV-positive patients with congenital clotting disorders.
Sartori MT; Mares M; Zerbinati P; Stocco D; Girolami A
Haematologia (Budap); 1994; 26(1):17-27. PubMed ID: 7959371
[TBL] [Abstract][Full Text] [Related]
12. The impact of ethanol and Marinol/marijuana usage on HIV+/AIDS patients undergoing azidothymidine, azidothymidine/dideoxycytidine, or dideoxyinosine therapy.
Whitfield RM; Bechtel LM; Starich GH
Alcohol Clin Exp Res; 1997 Feb; 21(1):122-7. PubMed ID: 9046384
[TBL] [Abstract][Full Text] [Related]
13. Cytomegalovirus retinitis under combination therapy with zidovudine and dideoxycytidine in advanced human immunodeficiency virus infection.
Kaulen P; Pham DT; Baranowski E; Wollensak J
Ger J Ophthalmol; 1993 Nov; 2(6):412-5. PubMed ID: 8312826
[TBL] [Abstract][Full Text] [Related]
14. Acyclovir in combination with zidovudine does not prolong survival in advanced HIV disease.
Erbelding EJ; Chaisson RE; Gallant JE; Moore RD
Antivir Ther; 1997 Apr; 2(2):71-7. PubMed ID: 11322278
[TBL] [Abstract][Full Text] [Related]
15. Natural history of advanced HIV disease in patients treated with zidovudine. The Zidovudine Epidemiology Study Group.
Moore RD; Keruly J; Richman DD; Creagh-Kirk T; Chaisson RE
AIDS; 1992 Jul; 6(7):671-7. PubMed ID: 1503686
[TBL] [Abstract][Full Text] [Related]
16. A double-blind randomized placebo trial on very high doses of acyclovir in weakly symptomatic HIV-patients.
Chavanet P; Malet J; Waldner A; Aho S; Buisson M; Bielefeld P; Portier H
Cancer Detect Prev; 1990; 14(6):669-73. PubMed ID: 1979522
[TBL] [Abstract][Full Text] [Related]
17. Treatment initiation with zidovudine-containing potent antiretroviral therapy impairs CD4 cell count recovery but not clinical efficacy.
Huttner AC; Kaufmann GR; Battegay M; Weber R; Opravil M
AIDS; 2007 May; 21(8):939-46. PubMed ID: 17457087
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of treatment with AZT of patients with AIDS and symptomatic HIV infection.
Cox PH; Martin MA; Styer CM; Beall GN
Nurse Pract; 1990 May; 15(5):36, 39-44. PubMed ID: 2342666
[TBL] [Abstract][Full Text] [Related]
19. AIDS therapy with two, three or four agent combinations, applied in short sequences, differing from each other by drug rotation. I. First of two parts: a phase I trial equivalent, concerning five virostatics: AZT, ddI, ddC, acriflavine and an ellipticine analogue.
Mathé G; Pontiggia P; Orbach-Arbouys S; Triana K; Ambetima N; Morette C; Hallard M; Blanquet D
Biomed Pharmacother; 1996; 50(5):220-7. PubMed ID: 8949403
[TBL] [Abstract][Full Text] [Related]
20. A randomized controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV infection.
Vella S; Lazzarin A; Carosi G; Sinicco A; Armignacco O; Angarano G; Andreoni M; Tambussi G; Chiodera A; Floridia M; Scaccabarozzi S; Facey K; Duncan I; Boudes P; Bragman K
Antivir Ther; 1996 Aug; 1(3):129-40. PubMed ID: 11322246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
